Table 1 Baseline characteristics of locally advanced head & neck squamous cell carcinoma
Characteristics | Treatment Strategy | p-value* | |||
|---|---|---|---|---|---|
CCRT group n = 229 (51.5%) | Surgery group n = 187 (42.0%) | Inadequate Tx n = 29 (6.5%) | Total N = 445 (100%) | ||
Age, median [range], years | 61 [30–81] | 60 [24–89] | 0.633 | 67 [36–82] | 61 [24–89] |
Gender | 0.125 | ||||
Female | 25 (41.7%) | 30 (50.0%) | 5 (8.3%) | 60 (100%) | |
Male | 204 (53.0%) | 157 (40.8%) | 24 (6.2%) | 385 (100%) | |
ECOG PS | < 0.001 | ||||
0 | 40 (72.7%) | 9 (16.4%) | 6 (10.9%) | 55 (100%) | |
1 | 153 (71.2%) | 47 (21.9%) | 15 (7.0%) | 215 (100%) | |
2 | 12 (70.6%) | 3 (17.7%) | 2 (11.8%) | 17 (100%) | |
3 | 4 (100%) | 0 (0.0%) | 0 (0.0%) | 4 (100%) | |
Unknown | 20 (13.0%) | 128 (83.1%) | 6 (3.9%) | 154 (100%) | |
Smoking history | < 0.001 | ||||
Never | 37 (37.4%) | 54 (54.6%) | 8 (8.1%) | 99 (100%) | |
Former | 62 (46.3%) | 62 (46.3%) | 10 (7.5%) | 134 (100%) | |
Current | 53 (49.5%) | 46 (43.0%) | 8 (7.5%) | 107 (100%) | |
Unknown | 77 (73.3%) | 25 (23.8%) | 3 (2.9%) | 105 (100%) | |
Alcohol history | < 0.001 | ||||
Do not drink | 49 (40.8%) | 60 (50.0%) | 11 (9.2%) | 120 (100%) | |
Drink alcohol | 71 (43.6%) | 83 (50.9%) | 9 (5.5%) | 163 (100%) | |
Unknown | 109 (67.3%) | 44 (27.2%) | 9 (5.6%) | 162 (100%) | |
Primary tumor location | < 0.001 | ||||
Oropharynx | 105 (55.0%) | 73 (38.2%) | 13 (6.8%) | 191 (100%) | |
Oral cavity | 30 (28.3%) | 70 (66.0%) | 6 (5.7%) | 106 (100%) | |
Hypopharynx | 42 (65.5%) | 16 (25.0%) | 6 (9.4%) | 64 (100%) | |
Larynx | 31 (54.4%) | 24 (42.1%) | 2 (3.5%) | 57 (100%) | |
Others | 21 (77.8%) | 4 (14.8%) | 2 (7.4%) | 27 (100%) | |
Histologic grade | < 0.001 | ||||
Well differentiated | 22 (32.4%) | 41 (60.3%) | 5 (7.4%) | 68 (100%) | |
Moderate differentiated | 58 (36.5%) | 97 (61.0%) | 4 (2.5%) | 159 (100%) | |
Poorly differentiated | 42 (63.6%) | 21 (31.8%) | 3 (4.6%) | 66 (100%) | |
Not assessed | 107 (70.4%) | 28 (18.8%) | 17 (11.4%) | 152 (100%) | |
T classification | < 0.001 | ||||
T1 | 21 (31.8%) | 43 (65.2%) | 2 (3.0%) | 66 (100%) | |
T2 | 85 (49.4%) | 80 (46.5%) | 7 (4.1%) | 172 (100%) | |
T3 | 57 (60.6%) | 30 (31.9%) | 7 (7.5%) | 94 (100%) | |
T4a / T4b | 51 / 14 (58.6%) | 31 / 2 (29.7%) | 11 / 2 (11.7%) | 93 / 18 (100%) | |
Unknown | 1 (50.0%) | 1 (50.0%) | 0 (0.0%) | 2 (100%) | |
N classification | < 0.001 | ||||
N0 | 25 (48.1%) | 24 (46.2%) | 3 (5.8%) | 52 (100%) | |
N1 | 56 (40.0%) | 79 (56.4%) | 5 (3.6%) | 140 (100%) | |
N2 | 142 (58.0%) | 83 (33.9%) | 20 (8.2%) | 245 (100%) | |
N3 | 6 (85.7%) | 1 (14.3%) | 0 (0.0%) | 7 (100%) | |
Unknown | 0 (0.0%) | 0 (0.0%) | 1 (100%) | 1 (100%) | |
P16/HPV status | < 0.001 | ||||
Negative | 16 (16.2%) | 79 (79.8%) | 4 (4.0%) | 99 (100%) | |
Positive | 45 (50.0%) | 43 (47.8%) | 2 (2.2%) | 90 (100%) | |
Unknown | 168 (65.6%) | 65 (25.4%) | 23 (9.0%) | 256 (100%) | |